Thanks Baba. That makes sense.

Regarding your point on an overbought call market: "slightest bad news can cascade the market lower". What you think the effect may be vis-a-vis a mixed set of results in August with Afrezza. Say success on AF1 (superiorty vs. Humalog) and not as much on AF2 (vs. Metformin). I personally think a pull back maybe, even though that in itself is not a bad news.